NewGenIvf
NIVF
5 hedge funds and large institutions have $139K invested in NewGenIvf in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, reducing their positions, and closing their positions.
3,512% more capital invested
Capital invested by funds: $3.85K → $139K (+$135K)
67% more funds holding
Funds holding: 3 → 5 (+2)
1.19% more ownership
Funds ownership: 0.01% → 1.2% (+1.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$226K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$77.2K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$18.1K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$10.9K |
| 5 |
SS
SBI Securities
Tokyo,
Japan
|
+$139 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$2 |
NIVF Hedge Fund Activity: Q2 2026 in Review
5 of the 8,349 institutional investors tracked by Wall St. Rank reported a position in NewGenIvf (NIVF) for Q2 2026, worth a combined $139K — up 3,512% from $3.85K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new NIVF positions and 0 closed out — a net gain of 2 holders — while 3 added to existing stakes and 0 trimmed.
The largest buyer was HRT Financial, opening a new position worth an estimated $226K. The largest seller was Morgan Stanley, cutting an estimated $2.
- 5 institutional investors held NewGenIvf (NIVF) as of Q2 2026, up from 3 in Q1 2026.
- Funds reported $139K of NewGenIvf stock for Q2 2026, up 3,512% quarter-over-quarter.
- 2 funds opened new NewGenIvf positions in Q2 2026 and 0 closed out, a net change of +2 holders.
- The largest NewGenIvf buyer in Q2 2026 was HRT Financial, an estimated $226K added.
- The largest NewGenIvf seller in Q2 2026 was Morgan Stanley, an estimated $2 sold.
Based on aggregated 13F filings for Q2 2026.